Hemostatic Efficacy of Pathogen-Inactivated Blood Components.
Chicago, United States. In Semin Thromb Hemost, Jan 2016
UNASSIGNED: Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities.
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
Chapel Hill, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
For more than 3 decades, the scientific community has pursued gene correction of hemophilia, with the goal that an individual with congenitally deficient factor VIII or factor IX might synthesize adequate endogenous clotting factor to be relieved of burdensome repeated clotting factor infusions, as well as the emotional weight of continuous hemorrhage risk.
Acquired bleeding disorders in the elderly.
Seattle, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow.
Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.
In Lancet Hiv, Dec 2015
Individuals were eligible if enrolled in a cohort that collected information on geographical origin or ethnic origin from Jan 1, 1997, to March 19, 2013, aged 18-75 years, they had available information about sex, they were not infected perinatally or after the receipt of clotting factor concentrates, and were naive to combination antiretroviral therapy at cohort entry.
Modern haemophilia care.
Malmö, Sweden. In Lancet, 2012
Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s.
Nanoparticles for the delivery of genes and drugs to human hepatocytes.
Ibaraki, Japan. In Nat Biotechnol, 2003
When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes.